NCT04807257View on ClinicalTrials.gov

Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Malignant Fungating Wound
Interventions
COMBINATION_PRODUCT

Auger Molecular Therapy (AMT)

The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.

Trial Locations (1)

110

RECRUITING

Taipei Medical University Hospital, Taipei

All Listed Sponsors
lead

NanoRay Biotech Co., Ltd.

INDUSTRY